Fig. 1: Identification of Ran as a candidate substrate of USP13.

A Gene expression profiling (GEP) data showing USP13 expression in DLBCL: 47 patient samples and 337 normal control tissues. The figure was plotted from TCGA and GEPIA datasets. B The expression of USP13 in different DLBCL stages, and the figure was plotted from TCGA and GEPIA datasets. C Schematic diagram showing the process of USP13 substrate identification using quantitative proteomics by LC-MS/MS system. D Venn diagram showing the number of up-regulated proteins identified with USP13 overexpression (blue) and proteins of USP13 interactome identified in Co-IP process (green). The chart below showed the overlapped proteins. E GEP data showing Ran (left) and TUBB (right) expression in DLBCL: 47 patient samples and 337 normal control tissues. The figure was plotted from TCGA and GEPIA datasets. F The correlation analysis of USP13 and Ran (left, R = 0.43, P = 0.0023) or USP13 and TUBB (right, R = 0.75, P = 1.7e-09) in DLBCL samples plotted from TCGA and GEPIA datasets. G Immunoblots of the lysates from HEK293T transfected with empty vector (EV) and GFP-USP13 for 48 h. H Quantitative PCR analysis of USP13, Ran, and TUBB mRNA levels in HEK293T cells upon USP13 overexpression (N.S. not significant; ****P < 0.0001). I Copy number variation analysis of USP13 and Ran in TCGA DLBCL samples (DLBC cohort) with genomic deletion in blue and amplification in red. J Representative images for immunohistochemical staining of USP13 and Ran in human DLBCL tissue (scale bar: 50 μm). K Immunoblots for indicated proteins of lysates from normal B lymphocytes and a panel of DLBCL cell lines. N = 3 individual experiments and representative images are shown.